Hemogenyx Short Term Debt from 2010 to 2024
| HEMO Stock | 343.40 20.90 6.48% |
Short Term Debt | First Reported 2010-12-31 | Previous Quarter 273.1 K | Current Value 318 K | Quarterly Volatility 414.7 K |
Check Hemogenyx Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hemogenyx Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 365.3 K, Selling General Administrative of 5.2 M or Other Operating Expenses of 6.8 M, as well as many indicators such as . Hemogenyx financial statements analysis is a perfect complement when working with Hemogenyx Pharmaceuticals Valuation or Volatility modules.
Hemogenyx | Short Term Debt |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hemogenyx Stock Analysis
When running Hemogenyx Pharmaceuticals' price analysis, check to measure Hemogenyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemogenyx Pharmaceuticals is operating at the current time. Most of Hemogenyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hemogenyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemogenyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hemogenyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.